Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAL: Abacavir/Lamivudine FDC QD vs BID
NCT00046176Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2002
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of abacavir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Aug 2002; status: completed.
02
Drugs
abacavir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00046176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046176.